---
title: "Stock Analysis: Raffles Medical Group | Lianhe Zaobao"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273679917.md"
description: "Raffles Medical Group recommends buying, with a target price of 1.15 yuan and a closing price of 1.00 yuan. It is expected that net profit will increase by 16% year-on-year in the second half of 2025, continuing into 2026 and 2027, achieving double-digit growth. Benefiting from the recovery of local hospital business and improvement in insurance business, the reform of comprehensive health insurance plans will help curb medical cost inflation. Raffles Medical's insurance premiums remain unchanged, providing a competitive advantage. Other catalysts include the improvement of hospital revenue and expenditure balance in China and the advancement of acquisition cases in Vietnam"
datetime: "2026-01-26T09:33:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273679917.md)
  - [en](https://longbridge.com/en/news/273679917.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273679917.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273679917.md) | [繁體中文](https://longbridge.com/zh-HK/news/273679917.md)


# Stock Analysis: Raffles Medical Group | Lianhe Zaobao

**Raffles Medical Group**

-   Recommendation: Buy
-   Target Price: 1.15 SGD
-   Closing Price: 1.00 SGD (no change)

After two years of declining performance, Raffles Medical Group is expected to return to growth in the second half of 2025.

Benefiting from the recovery of local hospital business, reduced drag from China operations, and improved profitability in the insurance business, we expect the group's net profit attributable to minority shareholders to increase by 16% year-on-year in the second half of 2025, with momentum likely to continue into 2026 and 2027, achieving double-digit growth in both years.

#### Further Reading

Stock Evaluation: Yiziyuan Stock Evaluation: DFI Retail Group

In addition, the comprehensive health insurance plan supplementary insurance reform implemented by the authorities in April will help curb medical cost inflation in the long run, supporting the affordability and sustainable demand for private healthcare. Raffles Health Insurance (RHI) has maintained stable premiums for two consecutive years, providing a competitive advantage.

Other catalysts for the stock price include improved financial balance of Chinese hospitals and progress in acquisitions in Vietnam. (Industrial Bank Research)

### 相关股票

- [Raffles Medical (BSL.SG)](https://longbridge.com/zh-CN/quote/BSL.SG.md)

## 相关资讯与研究

- [Raffles Medical CEO tightens grip with $0.99 share sweep](https://longbridge.com/zh-CN/news/280728726.md)
- [Raffles Medical Group: Solid Balance Sheet and Earnings Inflection Underscore Attractive Entry Point](https://longbridge.com/zh-CN/news/271645484.md)
- [VietNam Holding Narrows Discount as Vietnam’s Reforms and Growth Bolster Outlook](https://longbridge.com/zh-CN/news/280965185.md)
- [Bank of Iwate Unveils Inflation-Era Medium-Term Plan With Higher Profit and ROE Targets](https://longbridge.com/zh-CN/news/280958985.md)
- [Pendle joins Vietnam IFC delegation alongside BlackRock, Morgan Stanley, and Deutsche Bank](https://longbridge.com/zh-CN/news/281129902.md)